ACC 2017: Late-Breaking Clinical Trials
Research includes safety of digoxin with atrial fibrillation, comparison of cerebral embolic protection devices, and cerebral microbleed triggers.
ACC 2017: CV Risk Factors
Research includes a possible link between Zika & CV issues, CV effects of cannabis use, and neurocognitive impairment with PCSK9 variants.
ACTRIMS 2017 Forum: MS Treatment Clinical Trials
Research examined no evidence of disease activity and no evidence of progression with ocrelizumab as well as long-term results with mitoxantrone.
ISC 2017: Vascular Cognitive Impairment
Research included the impact of diet on cognitive decline and the degree of a link between depression & dementia post intracerebral hemorrhage.
Cognitive and Psychiatric Impairment in Parkinson
Can we see changes in the brain that correspond to cognitive difficulties? Research presented at AAN 2016 offers compelling information.
Impact of Epilepsy on Other Neurological Disorders
Research from AES 2016 explored relationships between epilepsy and other neurological disorders, including Alzheimer disease, MS, stroke, and autism.
Epilepsy: Psychological & Behavioral Interventions
There is a pressing need for effective interventions aimed at enhancing psychological well-being and self-management for epilepsy patients.
Exploratory Trial for Essential Tremor Treatment
In a proof-of-concept study, 25 patients were exposed to a dose-escalating infusion of SAGE-547 to evaluate the drug’s effect on essential tremor.
Modeling Simulations to Predict AED Efficacy
Researchers used simulations to predict the outcomes of epilepsy patients with partial-onset seizures converting to Aptiom monotherapy (800 mg QD).
Potential Treatment for SRSE
Research leading up to the ongoing phase 3 trial of SAGE-547, a potential drug for super-refractory status epilepticus, was presented at AAN 2016.
Antiepileptic Drug Choice: Patient vs Neurologist
Do you and your patients with epilepsy agree on treatment decisions? A national survey compares AED attribute preferences of patients and neurologists.
By clicking Accept, you agree to become a member of the UBM Medica Community.